Freshworks Inc., a software development company, provides software-as-a-service products in North America, Europe, the Middle East, Africa, the Asia Pacific, and internationally.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.02, read 2026-11-03
Ethical passes the values gate
Price13.26 USD
Fair value18.31
Ethical score70.0/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-11Read Accumulation12.78+3.8% to today ✓Markdown gives way to Accumulation
2026-10-02Read Markdown12.45+6.5% to today Markup gives way to Markdown after a 32% rise in 13 weeks
2026-07-02Read Markup9.45+40.4% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Freshworks Inc. holds its Accumulation at $13.26. The statistical read favours the buyers, held for 86 days.
As held on the ledger · 2026-11-04
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 86 days
Price at the screen
$13.26
Valuation
21.05 trailing · 15.94 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.76
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.65%
Below 33%
Interest-bearing debt is just 2.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
13.20%
Below 33%
Cash held in interest-bearing accounts and securities is 13.2% of assets, under the one-third limit.
Pass
Receivables
44.96%
Below 49%
Money owed to the company is 45.0% of assets, under the 49% limit.
Pass
Revenue purity
4.55%
Below 5%
Only 4.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Freshworks clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 3%, inside the ~33% line, and interest is about 5% of its income, under the ~5% line, so it passes.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when FRSH's ethical verdict changes
Today FRSH passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 28% discount to our $18.31 fair value, 16.00% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 27.6% discount to the base estimate.
Where our models see it going: fair-value estimate $18.31, with a range of $16.22 to $26.52, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Freshworks powers chat windows few remember
Picture the pop-up chat that appears the moment you buy something online. Freshworks builds the software behind many of those conversations, yet the market treats the business as interchangeable with dozens of rivals. Our screen finds nothing objectionable on ethics grounds and the numbers are respectable, yet the opportunity rating sits at none because the shares already price in most of the visible progress.
Revenue is still rising at 16 percent and the firm converts that into a 21 percent profit margin with a 17 percent return on equity. Forward earnings sit at just 13.6 times, but twelve analysts see only modest upside and place their median target at 11 dollars, barely above the current 10.89. A 26 percent gap to our own fair value of 13.75 exists on paper, yet the absence of any moat rating leaves the edge too thin to act on.
Competition in customer and employee experience tools remains fierce and currency or spending cuts could trim growth quickly. The shares look fairly valued rather than cheap once those realities are weighed. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
FRSH trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Accumulation$14.21-3.5%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (12 analysts) rates it buy, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$14.72+0.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (12 analysts) rates it buy, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Accumulation$14.72+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (12 analysts) rates it buy, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Accumulation$14.72-1.9%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (12 analysts) rates it buy, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Accumulation$15.01-2.4%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (12 analysts) rates it buy, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$15.38+3.7%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (12 analysts) rates it buy, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$14.83+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (12 analysts) rates it buy, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$14.83+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (12 analysts) rates it buy, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$14.83+4.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (12 analysts) rates it buy, with a mean price target of $12.
2026-10-18Accumulation$14.25+11.5%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 11.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (12 analysts) rates it buy, with a mean price target of $12.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
